Completed
Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS
NCT00744536
- Conditions
- Angiogenesis, Bone Marrow Diseases, Chronic Disease, +12 more
- Locations
-
- Sunnybrook Health Sciences Centre, Odette Cancer Center Toronto, Ontario, Canada